Literature DB >> 2070568

A defect in the protein kinase C system in T cells from patients with systemic lupus erythematosus.

Y Tada1, K Nagasawa, Y Yamauchi, H Tsukamoto, Y Niho.   

Abstract

To determine whether there is an intrinsic defect in T cells from patients with systemic lupus erythematosus (SLE), we studied signal transduction systems, assaying the total protein kinase C (PKC) levels and the phorbol myristate acetate (PMA)-induced activation of PKC in PHA-treated T cells. T cells from SLE patients showed a decrease in proliferation in response to PMA, but not to PHA, thereby suggesting the existence of an intrinsic abnormality in the PKC-mediated activation pathway. Total PKC activity in the T cells from SLE patients was significantly decreased. Although stimulation with PMA induced a translocation of PKC from the cytosol to the particulate fraction, translocated PKC activity after 2 nM PMA treatment was decreased in the SLE T cells. Furthermore, PMA-induced phosphorylation of 80-kDa substrates was also decreased in SLE T cells. These results suggest that there is a reduced PKC activity and an impaired PKC activation in response to PMA in the SLE T cells, a finding which may explain, if partially, the defect in T cell activation in patients with SLE.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2070568     DOI: 10.1016/0090-1229(91)90065-i

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  12 in total

1.  Glucocorticosteroid dependent decrease in the activity of calcineurin in the peripheral blood mononuclear cells of patients with systemic lupus erythematosus.

Authors:  S Sipka; K Szucs; S Szántó; I Kovács; G Lakos; E Kiss; P Antal-Szalmás; G Szegedi; P Gergely
Journal:  Ann Rheum Dis       Date:  2001-04       Impact factor: 19.103

2.  Systemic lupus erythematosus serum IgG increases CREM binding to the IL-2 promoter and suppresses IL-2 production through CaMKIV.

Authors:  Yuang-Taung Juang; Ying Wang; Elena E Solomou; Yansong Li; Christian Mawrin; Klaus Tenbrock; Vasileios C Kyttaris; George C Tsokos
Journal:  J Clin Invest       Date:  2005-04       Impact factor: 14.808

3.  Altered regulation of IL-2 production in systemic lupus erythematosus: an evolving paradigm.

Authors:  Gary M Kammer
Journal:  J Clin Invest       Date:  2005-04       Impact factor: 14.808

4.  Protein phosphatase 2A is a negative regulator of IL-2 production in patients with systemic lupus erythematosus.

Authors:  Christina G Katsiari; Vasileios C Kyttaris; Yuang-Taung Juang; George C Tsokos
Journal:  J Clin Invest       Date:  2005-10-13       Impact factor: 14.808

Review 5.  Immune cell signaling aberrations in human lupus.

Authors:  S N Liossis; P P Sfikakis; G C Tsokos
Journal:  Immunol Res       Date:  1998-08       Impact factor: 2.829

Review 6.  Therapeutic potential of protein kinase C inhibitors.

Authors:  D Bradshaw; C H Hill; J S Nixon; S E Wilkinson
Journal:  Agents Actions       Date:  1993-01

7.  Defective expression and tyrosine phosphorylation of the T cell receptor zeta chain in peripheral blood T cells from systemic lupus erythematosus patients.

Authors:  M Pang; Y Setoyama; K Tsuzaka; K Yoshimoto; K Amano; T Abe; T Takeuchi
Journal:  Clin Exp Immunol       Date:  2002-07       Impact factor: 4.330

8.  PP2A dephosphorylates Elf-1 and determines the expression of CD3zeta and FcRgamma in human systemic lupus erythematosus T cells.

Authors:  Yuang-Taung Juang; Ying Wang; Guisen Jiang; Hai-Bin Peng; Sukran Ergin; Michelle Finnell; Abigail Magilavy; Vasileios C Kyttaris; George C Tsokos
Journal:  J Immunol       Date:  2008-09-01       Impact factor: 5.422

9.  Analysis of proteins that interact with the IL-2 regulatory region in patients with rheumatic diseases.

Authors:  H Becker; G Stengl; M Stein; K Federlin
Journal:  Clin Exp Immunol       Date:  1995-03       Impact factor: 4.330

Review 10.  The role of epigenetic variation in the pathogenesis of systemic lupus erythematosus.

Authors:  Travis Hughes; Amr H Sawalha
Journal:  Arthritis Res Ther       Date:  2011-10-31       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.